Literature DB >> 11313871

The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.

M Argentini1, N Barboule, B Wasylyk.   

Abstract

p53 and MDM2 are both degraded by the ubiquitin-proteasome pathway. MDM2 binds p53 and promotes its rapid degradation. MDM2 is an E3 ligase that activates self and p53 ubiquitylation. Moreover, MDM2 nuclear-cytoplasmic shuttling contributes to p53 degradation in the cytoplasm. We have identified a new region of MDM2 which regulates the stability of both p53 and MDM2. The first 50 amino-acids of the MDM2 acidic domain (222-272) contribute to MDM2 and MDM2-mediated p53 degradation by a mechanism which is independent of either MDM2 E3-ligase activity or MDM2 nucleo-cytoplasmic shuttling. The transcriptional coactivator p300 could have been involved, since it binds to the MDM2 acidic domain. However, we found that p300 stabilises MDM2, even in absence of an intact acidic domain, indicating that the MDM2 acidic region contributes to proteolysis independently of p300. We propose that the MDM2 acidic domain is required for unbiquitylated MDM2 and p53 to be degraded by cytoplasmic proteasomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313871     DOI: 10.1038/sj.onc.1204241

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.

Authors:  R Stad; N A Little; D P Xirodimas; R Frenk; A J van der Eb; D P Lane; M K Saville; A G Jochemsen
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

2.  Hypophosphorylation of Mdm2 augments p53 stability.

Authors:  Christine Blattner; Trevor Hay; David W Meek; David P Lane
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

3.  ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression.

Authors:  Lionel Le Gallic; Laura Virgilio; Philip Cohen; Benoit Biteau; George Mavrothalassitis
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

4.  Critical role for a central part of Mdm2 in the ubiquitylation of p53.

Authors:  Erik Meulmeester; Ruth Frenk; Robert Stad; Petra de Graaf; Jean-Christophe Marine; Karen H Vousden; Aart G Jochemsen
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

5.  Critical contribution of the MDM2 acidic domain to p53 ubiquitination.

Authors:  Hidehiko Kawai; Dmitri Wiederschain; Zhi-Min Yuan
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

6.  Mdm2 facilitates the association of p53 with the proteasome.

Authors:  Roman Kulikov; Justine Letienne; Manjit Kaur; Steven R Grossman; Janine Arts; Christine Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

7.  HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication.

Authors:  Taisuke Izumi; Katsuhiro Io; Masashi Matsui; Kotaro Shirakawa; Masanobu Shinohara; Yuya Nagai; Masahiro Kawahara; Masayuki Kobayashi; Hiroshi Kondoh; Naoko Misawa; Yoshio Koyanagi; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-11       Impact factor: 11.205

8.  Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.

Authors:  X Zhang; W Wang; H Wang; M-H Wang; W Xu; R Zhang
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

9.  Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.

Authors:  Mikael S Lindström; Aiwen Jin; Chad Deisenroth; Gabrielle White Wolf; Yanping Zhang
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

10.  Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26.

Authors:  Yaara Ofir-Rosenfeld; Kristy Boggs; Dan Michael; Michael B Kastan; Moshe Oren
Journal:  Mol Cell       Date:  2008-10-24       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.